Literature DB >> 16710433

Ocular morbidity associated with intravitreal triamcinolone acetonide.

A Konstantopoulos1, C P R Williams, R S Newsom, A J Luff.   

Abstract

AIM: To report on the complications associated with the use of intravitreal triamcinolone acetonide (IVTA) in a tertiary referral hospital setting.
MATERIALS AND METHODS: A retrospective case series review of all IVTA injections carried out over a period of 30 months.
RESULTS: One hundred and thirty IVTA injections were performed; nine with limited local follow-up were excluded. Thus, 121 injections (108 patients, 114 eyes) were included in the study. Triamcinolone (4 mg) was used in all cases. Indications were diabetic macular oedema (n=41 eyes), retinal vein occlusions (n=27), postoperative cystoid macular oedema (n=24), exudative age-related macular degeneration (n=16), and others (n=6). No intraoperative complications were recorded. Postoperative intraocular pressure (IOP) readings of 22, 28, 35, and 40 mmHg or higher were recorded in 46.5, 29.8, 12.3, and 7.9% of eyes, respectively. IOP elevation was treated with antiglaucoma medication in all but one eye (0.9%) that required trabeculectomy and one (0.9%) that required vitrectomy with cataract extraction for suspected phacoanaphylactic glaucoma. Two eyes (1.8%) developed retinal detachment; both had previously been treated for retinal breaks. One eye (0.9%) developed culture-positive endophthalmitis.
CONCLUSIONS: Significant morbidity is associated with IVTA injection; clinicians should be aware when considering treatment options.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16710433     DOI: 10.1038/sj.eye.6702416

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  15 in total

1.  Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.

Authors:  A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-04-17       Impact factor: 4.638

2.  Safety of intravitreal triamcinolone acetonide: an electrophysiologic and histopathological study in rabbits.

Authors:  Laila Hassan M El-Shazly; Amal Ahmad El-Gohary; Ghada Ghanem El-Hossary
Journal:  Int J Ophthalmol       Date:  2013-12-18       Impact factor: 1.779

3.  Effect of posterior sub-tenon triamcinolone in macular edema due to non-ischemic vein occlusions.

Authors:  Murali Mohan Gurram
Journal:  J Clin Diagn Res       Date:  2013-09-13

4.  Treatment of steroid-induced elevated intraocular pressure with anecortave acetate: a randomized clinical trial.

Authors:  Ingeborg Stalmans; David G Callanan; Monte S Dirks; Marlene R Moster; Alan L Robin; Joachim Van Calster; Sally A Scheib; Jaime E Dickerson; Theresa A Landry; Michael V W Bergamini
Journal:  J Ocul Pharmacol Ther       Date:  2012-08-03       Impact factor: 2.671

Review 5.  Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.

Authors:  Dina Gewaily; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

6.  One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study.

Authors:  Juan-Carlos Gutiérrez-Hernández; Sean Caffey; Walid Abdallah; Phillip Calvillo; Roberto González; Jason Shih; Jeff Brennan; Jenna Zimmerman; Juan-Carlos Martínez-Camarillo; Anthony R Rodriguez; Rohit Varma; Arturo Santos; Gisela Sánchez; Mark Humayun
Journal:  Transl Vis Sci Technol       Date:  2014-07-01       Impact factor: 3.283

Review 7.  Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.

Authors:  Dina Gewaily; Karthikeyan Muthuswamy; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2015-09-09

8.  Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema.

Authors:  Ju Hwan Song; Jung Joo Lee; Sang Joon Lee
Journal:  Korean J Ophthalmol       Date:  2011-05-24

9.  Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema.

Authors:  Hatem M Marey; Amin F Ellakwa
Journal:  Clin Ophthalmol       Date:  2011-07-22

10.  Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection.

Authors:  Eun Jee Chung; Hyoung Jun Koh
Journal:  Korean J Ophthalmol       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.